Dissection of CDK4-binding and transactivation activities of p34 SEI-1 and comparison between functions of p34SEI-1 and p16INK4A

Biochemistry

Volumn 44, Issue 40, 2005, Pages 13246-13256

  Li, Junan ^a,c   Muscarella, Peter ^a,b   Joo, Sang Hoon ^c   Knobloch, Thomas J ^c   Melvin, W Scott ^a,b   Weghorst, Christopher M ^b,c   Tsai, Ming Daw ^b,c,d  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGENS; FUNCTIONS; GENES; MUTAGENESIS;

BINDING ANALYSIS; CDK4-BINDING AND TRANSACTIVATION; CELL-CYCLE PROGRESSION; INHIBITORY ACTIVITY;

CELL CULTURE;

CYCLIN D2; CYCLIN DEPENDENT KINASE 4; LEXA PROTEIN; MUTANT PROTEIN; PROTEIN P16; PROTEIN P16INK4A; PROTEIN P34SEI 1; PROTEIN TRIP BR1; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; SITE DIRECTED MUTAGENESIS; SQUAMOUS CELL CARCINOMA; TRANSACTIVATION; TWO HYBRID SYSTEM;

AMINO ACID SEQUENCE; CARCINOMA, SQUAMOUS CELL; CLONING, MOLECULAR; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; MUTAGENESIS, SITE-DIRECTED; MUTATION; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 26444506187     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0504658     Document Type: Article

References (31)

1. Hsu, S. I.-H., Yang, C. M., Sim, K. G., Hentschel, D., O'Leary, E., and Bonventre, J. V. (2001) TRIP-Br: A novel family of PHD zinc finger- and bromodomain-interacting proteins that regulate the transcriptional activity of E2F1/Dp-1, EMBO J. 20, 2273-2285.
2. Sugimoto, M., Nakamura, T., Ohtani, N., Hampson, L., Hampson, I. N., Shimamoto, A., Furuichi, Y., Okumura, K., Niwa, S., Taya, Y., and Hara, E. (1999) Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1), Genes Dev. 13, 3027-3033.
3. SEI-1 regulates the kinase activity of cyclin-dependent kinase 4 in a concentration-dependent manner, Biochemistry 43, 4394-4399.
4. Tang, T. C.-M., Sham, J. S. T., Xie, D., Fang, Y., Huo, K.-K., Wu, Q.-L., and Guan, X.-Y. (2002) Identification of a candidate oncogene SEI-1 within a minimal amplified region at 19q13 in ovarian cell lines, Cancer Res. 62, 7157-7161.
5. van Dekken, H., Alers, J. C., Riegman, P. H., Rosenberg, C., Tilanus, H. W., and Vissers, K. (2001) Molecular cytogenetic evaluation of gastric cardia adenocarcinoma and precursor lesions, Am. J. Pathol. 158, 1961-1967.
6. Hoglund, M., Gorunova, L., Andren-Sandberg, A., Dawiskiba, S., Mitelman, F., and Johansson, B. (1998) Cytogenetic and fluorescence in situ hybridization analyses of chromosome 19 aberrations in pancreatic carcinomas: frequent loss of 19p13.3 and gain of 19q13.1-13.2, Genes, Chromosomes Cancer 21, 8-16.
7. Thompson, F. H., Nelson, M. A., Trent, J. M., Guan, X. Y., Liu, Y., Yang, J. M., Emerson, J., Adair, D. S., and Taetle, R. (1996) Amplification of 19q13.1-q13.2 sequences in ovarian cancer G-band, FISH, and molecular studies, Cancer Genet. Cytogenet. 87, 55-62.
8. Li, J., Li, H., and Tsai, M.-D. (2003) Direct binding of the N-terminus of HTLV-1 Tax oncoprotein to cyclin-dependent kinase 4 is a dominant path to stimulate the kinase activity, Biochemistry 42, 6921-6928.
9. BD Clontech (2001) MATCHMAKER LexA Two-Hybrid System, PT3030-1.
10. Li, J., and Tsai, M.-D. (2002) Novel insights into the INK4-CDK4/ 6-Rb pathway: Counter action of gankyrin against INK4 protein regulates the CDK4-mediated phosphorylation of Rb, Biochemistry 41, 3977-3983.
11. Byeon, I.-J. L., Li, J., Ericson, K., Selby, T. L., Tevelev, A., Kim, H. K., O'Maille, P., and Tsai, M.-D. (1998) Tumor suppressor p16INK4A: Determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4, Mol. Cell 1, 421-431.
12. Li, J., Joo, S. H., and Tsai, M.-D. (2003) An NF-kappaB-specific inhibitor, IκBα, binds to and inhibits cyclin-dependent kinase 4, Biochemistry 42, 13476-13483.
13. Lang, J. C., Borchers, J., Donahey, D., Smoth, S., Stover, D. G., Agrawal, A., Malone, J. P., Schuller, D. E., Weghorst, C. M., Holinga, A. J., Lingam, K., Patel, C. R., and Esham, B. (2002) Mutational status of overexpressed p16 in head and neck cancer: Evidence of germline mutation of p16/p14ARF, Int. J. Oncol. 21, 401-408.
14. INK4A/CDKN2A alterations in chemically induced Syrian golden hamster pancreatic tumors, Carcinogenesis 25, 263-268.
15. Hu, L. H., Chen, F. H., Li, Y. R., and Wang, I. (2004) Real-time determination of human telomerase reverse transcriptase mRNA in gastric cancer, World J. Gastroenterol. 10, 3514-3517.
16. Holland, E. A., Schmid, H., Kefford, R. F., and Mann, G. J. (1999) CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas, Genes, Chromosomes Cancer 25, 339-348.
17. Coleman, K. G., Wautlet, B. S., Morrissey, D., Mulheron, J., Sedman, S. A., Brinkley, P., Price, S., and Webster, K. R. (1997) Identification of CDK4 sequences involved in cyclin D1 and p16 binding, J. Biol. Chem. 272, 18869-18874.
18. Sotillo, R., Garcia, J. F., Ortega, S., Martin, J., Dubus, P., Barbacid, M., Malumbres, M. (2001) Invasive melanoma in CDK4-targeted mice, Proc. Natl. Acad. Sci. U.S.A. 98, 13312-13317.
19. INK4A, Nature 395, 237-243.
20. Brotherton, D. H., Dganaraj, V., Wick, S., Brizula, L., Domaille, P. J., Volyanik, E., Xu, X., Parisin, E., Smith, B. O., Archer, S. J., Serrano, M., Brenner, S. L., Blundell, T. L., and Laue, E. D. (1998) Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d, Nature 395, 244-250.
21. Poi, M. J., Yen, J., Li, J., Song, H., Lang, J. C., Schuller, D. E., Pearl, D. K., Casto, B. C., Tsai, M.-D., and Weghorst, C. M. (2001) Somatic INK4a-ARF locus mutations: A significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck, Mol. Carcinog. 30, 26-36.
22. Sim, K. G., Zang, Z., Yang, C. M., Bonventre, J. V., and Hsu, S. I. (2004) TRIP-Br links E2F to novel functions in the regulation of cyclin E expression during cell cycle progression and in the maintenance of genomic stability, Cell Cycle 3, 1296-1304.
23. Dong, Y., Walsh, M. D., McGuckin, M. A., Gabrielli, B. G., Cummings, M. C., Wright, R. G., Hurst, T., Khoo, S. K., and Parsons, P. G. (1997) Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis, Int. J. Cancer 74, 57-63.
24. Henshall, S. M., Quinn, D. I., Lee, C. S., Head, D. R., Golovsky, D., Brenner, P. C., Delprado, W., Stricker, P. D., Grygiel, J. J., and Sutherland, R. L. (2001) Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients, Clin. Cancer Res. 7, 544-550.
25. INK4a messenger RNA is a marker of poor prognosis, Clin. Cancer Res. 6, 2777-2787.
26. Milde-Langosch, K., Bamberger, A. M., Rieck, G., Kelp, B., and Loning, T. (2001) Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype, Breast Cancer Res. Treat. 67, 61-70.
27. Omura-Minamisawa, M., Diccianni, M. B., Chang, R. C., Batova, A., Bridgeman, L. J., Schiff, J., Cohn, S. L., London, W. B., and Yu, A. L. (2001) p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease, Clin. Cancer Res. 7, 3481-3490.
28. Fingeman, I. M., and Briggs, S. D. (2004) p53-mediated transcriptional activation: From test tube to cell, Cell 117, 690-691.
29. Bertrand, P., Saintigny, Y., and Lopez, B. S. (2004) p53's double life: Transactivation-independent repression of homologous recombination, Trends Genet. 20, 235-243.
30. Jeang, K. T., Giam, C. Z., Majone, F., and Aboud, M. (2004) Life, death, and tax: Role of HTLV-1 oncoprotein in genetic instability and cellular transformation, J. Biol. Chem. 279, 31991-31994.
31. Kehn, K., Berro, R., de la Fuente, C., Strouss, K., Ghedin, E., Dadgar, S., Bottazzi, M. E., Pumfery, A., and Kashanchi, F. (2004) Mechanims of HTLV 1 transformation, Front. Biosci. 9, 2347-2372.